Magrolimab联合利妥昔单抗联合或不联合化疗治疗复发/难治性弥漫大B细胞淋巴瘤患者
这项1b/2期研究报告了Magrolimab联合利妥昔单抗(M+R)治疗复发/难治性弥漫大B细胞淋巴瘤(DLBCL)的3年随访数据,以及M+R联合吉西他滨-奥沙利铂(M+R-GemOx)的初步安全性和疗效。132例患者中99例接受M+R、33例接受M+R-GemOx,M+R的客观缓解率(ORR)为24%、完全缓解(CR)率12%,M+R-GemOx的ORR为52%、CR率39%。结果表明两方案耐受性良好,M+R-GemOx在复发/难治性DLBCL中具有临床活性。
要点
- M+R组ORR 24%、CR 12%,中位缓解持续时间9.3个月,中位无进展生存期1.8个月、总生存期9.2个月。
- M+R-GemOx组ORR 52%、CR 39%,12个月缓解持续时间率66.6%(95%CI 33.1-86.1),中位无进展生存期3.9个月,中位总生存期未达到。
- 治疗相关不良事件导致Magrolimab停药的比例为M+R组7%、M+R-GemOx组6%,M+R-GemOx组有1例死亡被认为与治疗相关(结肠炎)。
核心结论
- 结果表明,M+R联合或不联合GemOx耐受性良好,M+R-GemOx在复发/难治性DLBCL患者中具有临床活性。
研究设计与样本
- 这项1b/2期研究评估M+R治疗复发/难治性DLBCL的长期安全性和疗效,以及M+R-GemOx的初步安全性和疗效,共治疗132例患者,其中99例接受M+R、33例接受M+R-GemOx。
- Magrolimab预激活后,4组患者接受M+R方案(Magrolimab 10至45 mg/kg联合利妥昔单抗375 mg/m2);接受M+R-GemOx的患者接受Magrolimab 30或45 mg/kg联合利妥昔单抗375 mg/m2、吉西他滨1000 mg/m2和奥沙利铂100 mg/m2。
- 主要终点为治疗中出现的不良事件(TEAE)和客观缓解率(ORR);次要终点包括缓解持续时间(DOR)、无进展生存期(PFS)和总生存期(OS)。
- 该试验在美国临床试验注册平台注册,注册号为NCT02953509。
主要发现
- 最常见任何级别TEAE为乏力(M+R组40%,M+R-GemOx组70%)、输注相关反应(M+R组39%)或贫血(M+R-GemOx组70%)。
- 治疗相关TEAE导致Magrolimab停药的比例为M+R组7%、M+R-GemOx组6%;M+R-GemOx组有1例死亡被认为与治疗相关(结肠炎)。
- M+R组ORR为24%(CR 12%),中位DOR为9.3个月,中位PFS和OS分别为1.8个月和9.2个月。
- M+R-GemOx组ORR为52%(CR 39%),12个月DOR率为66.6%(95%CI 33.1-86.1),中位PFS为3.9个月,中位OS未达到。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for available salvage therapies have limited options for long-term disease control, necessitating novel treatments. Previously, magrolimab (anti-cluster-of-differentiation-47 antibody) plus rituximab (M+R) demonstrated ability to induce complete responses (CR) in R/R DLBCL. Here, we report 3-year follow-up data from this phase 1b/2 study assessing long-term safety and efficacy of M+R, and initial safety and efficacy of M+R plus gemcitabine-oxaliplatin (M+R-GemOx), in R/R DLBCL. After magrolimab priming, 4 groups of patients received M+R, 10 to 45 mg/kg magrolimab with 375 mg/m2 rituximab; patients receiving M+R-GemOx received 30 or 45 mg/kg magrolimab with 375 mg/m2 rituximab, 1000 mg/m2 gemcitabine, and 100 mg/m2 oxaliplatin. Primary end points were treatment-emergent adverse events (TEAEs) and objective response rate (ORR). Secondary end points included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Of 132 patients treated, 99 received M+R and 33 received M+R-GemOx. Most common any-grade TEAEs were fatigue (M+R, 40%; M+R-GemOx, 70%), infusion-related reactions (M+R, 39%), or anemia (M+R-GemOx, 70%). Treatment-related TEAEs led to magrolimab discontinuation in 7% (M+R) and 6% (M+R-GemOx). One death was considered treatment related (M+R-GemOx, colitis). M+R ORR was 24% (CR, 12%), and median DOR was 9.3 months. Median PFS and OS were 1.8 and 9.2 months, respectively. M+R-GemOx ORR was 52% (CR, 39%); 12-month DOR rate was 66.6% (95% confidence interval, 33.1-86.1). Median PFS and OS were 3.9 months and not reached, respectively. These results demonstrate that M+R with/without GemOx is well tolerated, and M+R-GemOx has clinical activity in patients with R/R DLBCL. This trial was registered at www.clinicaltrials.gov as #NCT02953509.
引用
- Maakaron JE, Asch A, Popplewell L, et al. Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2024. PMID: 39293083. doi:10.1182/bloodadvances.2024013338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。